Photograph: Getty Images

The First Cancer ETF Tracks the Hottest Area of Biotech

Biotech investor Brad Loncar zeroes in on immunotherapies with a new fund.
Updated on

Launching a biotech exchange-traded fund after a big selloff in the sector isn’t the best timing. But Brad Loncar, a popular biotech blogger and investor, hopes people will be intrigued by the very specific and very hot slice of the biotech sector his new ETF focuses on—cancer immunotherapies.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.